OliX Pharmaceuticals and PCI Biotech announce a collaboration to combine OliX asiRNA and PCI Biotech fimaNAc technologies
05 mai 2021 05h00 HE
|
PCI Biotech Holding ASA
Suwon, South Korea and Oslo, Norway, May, 5th 2021 – OliX Pharmaceuticals Inc. (KOSDAQ: 226950) a leading developer of RNAi therapeutics, and PCI Biotech (OSE: PCIB), a cancer focused...
PCI Biotech: First US patient enrolled in the fimaChem pivotal RELEASE study
30 avr. 2021 15h00 HE
|
PCI Biotech Holding ASA
Oslo (Norway), 30 April 2021 – PCI Biotech (OSE: PCIB), a clinical-stage biopharma company developing innovative therapeutics that address significant unmet medical needs in cancer today announced...
PCI Biotech: Invitation to first quarter 2021 results presentation
30 avr. 2021 05h00 HE
|
PCI Biotech Holding ASA
Oslo, Norway, 30 April 2021 - PCI Biotech’s (OSE: PCIB) first quarter 2021 interim report will be released on 7 May 2021 at 07.00 CEST. The interim report and presentation will be made available on...
PCI Biotech Holding ASA publishes the Annual Report 2020
21 avr. 2021 03h05 HE
|
PCI Biotech Holding ASA
Oslo, Norway, April 21, 2021The Board of Directors of PCI Biotech Holding ASA has approved the Annual Report 2020 and the report is attached. The Annual Report 2020 is also available on the company’s...
PCI Biotech to present at European Biotech Investor Days 2021
06 avr. 2021 06h30 HE
|
PCI Biotech Holding ASA
Oslo (Norway), 6 April 2021 – PCI Biotech (OSE: PCIB), a clinical-stage biopharma company developing innovative therapeutics that address significant unmet medical needs in cancer today announced that...
PCI Biotech fourth quarter and preliminary full year 2020 results
24 févr. 2021 01h00 HE
|
PCI Biotech Holding ASA
Oslo (Norway), 24 February 2021 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announces its interim Q4 and preliminary full year 2020 results. Please find enclosed the...
PCI Biotech: Invitation to fourth quarter 2020 results presentation
18 févr. 2021 03h02 HE
|
PCI Biotech Holding ASA
Oslo, Norway, 18 February 2021 - PCI Biotech’s (OSE: PCIB) fourth quarter and preliminary full year 2020 interim report will be released on 24 February 2021 at 07.00 CET. The interim report and...
PCI Biotech - release of the RNA Therapeutics Virtual Conference presentation
10 févr. 2021 02h31 HE
|
PCI Biotech Holding ASA
Oslo (Norway), 10 February 2021 – PCI Biotech (OSE: PCIB), a clinical-stage biopharma company developing innovative therapeutics that address significant unmet medical needs in cancer today released...
PCI Biotech to present at RNA Therapeutics Virtual Conference
22 janv. 2021 06h04 HE
|
PCI Biotech Holding ASA
Oslo (Norway), 22 January 2021 – PCI Biotech (OSE: PCIB), a clinical-stage biopharma company developing innovative therapeutics that address significant unmet medical needs in cancer today announced...
PCI Biotech: Successful Phase I fimaVacc vaccination proof of concept study to be published in Frontiers in Immunology
23 nov. 2020 02h30 HE
|
PCI Biotech Holding ASA
Oslo (Norway), 23 November 2020 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announced that the results from the successful Phase I proof of concept study for the...